Ph.D. Candidate, Cancer Pharmacology
Matter of [Name not Provided], File No. EAC 99 120 50002 (AAO Feb. 26, 2004) (NIW granted)
The AAO sustained an appeal of a Vermont Service Center (VSC) denial of an NIW petition filed by a Ph.D. student studying pharmacology at Rutgers University and the University of Medicine and Dentistry of New Jersey. The petitioner studied DNA damage and repair in relation to cancer biology and cancer pharmacology:
Evidence Submitted
The petitioner submitted many witness letters from colleagues and experts in the field. One witness, a professor at the University of Medicine and Dentistry of New Jersey (UMDNJ) and Chairman of the Department of Pharmacology at UMDNJ, wrote:
[The petitioner] is the first person to demonstrate that DNA topoisomerase II is one of the enzymes involved in the breakdown of the chromosomes into the high molecular weight DNA fragments… This finding has great implications in developing new drugs and new treatment strategies for cancer patients
In another letter, the chief of the laboratory of molecular pharmacology at the National Cancer Institute described the petitioner’s discoveries. He stated that the petitioner’s “work in cancer research is extraordinary,” and his “research has clearly had a major impact on cancer research in the United States.” However, the AAO noted that the lab chief “did not elaborate or provide concrete examples of how the petitioner’s work has changed the direction of cancer research in the United States.”
Dr. Beppino Giovanella, laboratory director at the Stehlin Foundation for Cancer Research, Houston, Texas, who “only met [the petitioner] a couple of times at scientific meetings,” wrote more specifically about the impact of the petitioner’s work:
[The petitioner’s] recent publication on the role of DNA topoisomerase II in oxidative stress and cell death is of enormous importance in cancer and other medical research areas… This is the first demonstration of an important enzyme being involved in both cell proliferation and cell death. The implications of this finding are enormous… Certainly, [the petitioner’s] continued research in this new area is of critical importance to fully unveil the significance of this new finding
A professor of Duke University Medical Center concurred that the petitioner’s “work is highly significant,” indicating “new directions for research.”
The Approval
The AAO found that the witness letters provided by recognized experts were specific enough about the petitioner’s research contributions to demonstrate measurable influence to the larger field:
Upon consideration of the evidence and letters presented, we are persuaded that the petitioner’s work has made a significant impression not only on his mentors and collaborators, but also on independent researchers throughout the country. The reaction of these independent researchers goes beyond mere praise, indicating recognition of the petitioner’s work as having substantial significance.
Matter of [Name not Provided], File No. EAC 99 120 50002 (AAO Feb. 26, 2004) (NIW granted)
The AAO sustained an appeal of a Vermont Service Center (VSC) denial of an NIW petition filed by a Ph.D. student studying pharmacology at Rutgers University and the University of Medicine and Dentistry of New Jersey. The petitioner studied DNA damage and repair in relation to cancer biology and cancer pharmacology:
Evidence Submitted
The petitioner submitted many witness letters from colleagues and experts in the field. One witness, a professor at the University of Medicine and Dentistry of New Jersey (UMDNJ) and Chairman of the Department of Pharmacology at UMDNJ, wrote:
[The petitioner] is the first person to demonstrate that DNA topoisomerase II is one of the enzymes involved in the breakdown of the chromosomes into the high molecular weight DNA fragments… This finding has great implications in developing new drugs and new treatment strategies for cancer patients
In another letter, the chief of the laboratory of molecular pharmacology at the National Cancer Institute described the petitioner’s discoveries. He stated that the petitioner’s “work in cancer research is extraordinary,” and his “research has clearly had a major impact on cancer research in the United States.” However, the AAO noted that the lab chief “did not elaborate or provide concrete examples of how the petitioner’s work has changed the direction of cancer research in the United States.”
Dr. Beppino Giovanella, laboratory director at the Stehlin Foundation for Cancer Research, Houston, Texas, who “only met [the petitioner] a couple of times at scientific meetings,” wrote more specifically about the impact of the petitioner’s work:
[The petitioner’s] recent publication on the role of DNA topoisomerase II in oxidative stress and cell death is of enormous importance in cancer and other medical research areas… This is the first demonstration of an important enzyme being involved in both cell proliferation and cell death. The implications of this finding are enormous… Certainly, [the petitioner’s] continued research in this new area is of critical importance to fully unveil the significance of this new finding
A professor of Duke University Medical Center concurred that the petitioner’s “work is highly significant,” indicating “new directions for research.”
The Approval
The AAO found that the witness letters provided by recognized experts were specific enough about the petitioner’s research contributions to demonstrate measurable influence to the larger field:
Upon consideration of the evidence and letters presented, we are persuaded that the petitioner’s work has made a significant impression not only on his mentors and collaborators, but also on independent researchers throughout the country. The reaction of these independent researchers goes beyond mere praise, indicating recognition of the petitioner’s work as having substantial significance.
選擇“Disable on www.wenxuecity.com”
選擇“don't run on pages on this domain”
